ArticleMMWR. Morbidity and mortality weekly report2020
Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017.
Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 321 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer
Impact of Multimodal Telerehabilitation on Reducing Disparities in Rural Survivors of Metastatic Prostate Cancer
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate Cancer
Who cites it
321 citing papers in PubMed, 13 syntheses or guidelines pooled it.
- The Impact of Chronic Stress on Treatment Outcomes of Cancer Patients with Divergent Survival Rates: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Prostate-specific antigen velocity as a predictor of survival outcomes in patients with prostate cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pooled it
- Impact of Social Determinants of Health on Post-operative Outcomes Following Robotic Radical Prostatectomy.Current oncology reports · 2025Pooled it
- Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Weight gain or loss after diagnosis and survival outcomes in prostate cancer: a meta-analysis.BMC cancer · 2025Pooled it
- Association between soy products and prostate cancer: A systematic review and meta-analysis of observational studies.Investigative and clinical urology · 2024Pooled it
- Epidemiology of Cancer in Older Adults: A Systematic Review.Current oncology reports · 2024Pooled it
- Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.Prostate cancer and prostatic diseases · 2024Pooled it
- Association between polyphenol subclasses and prostate cancer: a systematic review and meta-analysis of observational studies.Frontiers in nutrition · 2024Pooled it
- Causal relationship between 150 skin microbiomes and prostate cancer: insights from bidirectional mendelian randomization and meta-analysis.Frontiers in immunology · 2024Pooled it
- The impact of race on survival in metastatic prostate cancer: a systematic literature review.Prostate cancer and prostatic diseases · 2023Pooled it
- Short-term home-based multimodal prehabilitation for perioperative functional recovery in prefrail and frail older men undergoing radical prostatectomy: a randomized controlled trial.BMC geriatrics · 2026Trial
- Functional outcomes of hypothermic robot assisted radical prostatectomy using BELLOCOOL in a randomized controlled trial.Scientific reports · 2025Trial
- Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO clinical cancer informatics · 2025Trial
- Safety, Dosimetry, and Feasibility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Androgen deprivation alone versus combined with pelvic radiation for adverse events and quality of life in clinically node-positive prostate cancer.Scientific reports · 2024Trial
- Trial
- Clinical significance of the combined systematic 12-core with concomitant MRI image-guided targeted prostate biopsy: can the MRI targeted biopsy stand on its own?International urology and nephrology · 2026Article
261 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among U.S. men, prostate cancer is the second leading cause of cancer-related death (1). Past studies documented decreasing incidence of prostate cancer overall since 2000 but increasing incidence of distant stage prostate cancer (i.e., signifying spread to parts of the body remote from the primary tumor) starting in 2010 (2,3). Past studies described disparities in prostate cancer survival by stage, age, and race/ethnicity using data covering ≤80% of the U.S. population (4,5). To provide recent data on incidence and survival of prostate cancer in the United States, CDC analyzed data from population-based cancer registries that contribute to U.S. Cancer Statistics (USCS).* Among 3.1 million new cases of prostate cancer recorded during 2003-2017, localized, regional, distant, and unknown stage prostate cancer accounted for 77%, 11%, 5%, and 7% of cases, respectively, but the incidence of distant stage prostate cancer significantly increased during 2010-2017. During 2001-2016, 10-year relative survival for localized stage prostate cancer was 100%. Overall, 5-year survival for distant stage prostate cancer improved from 28.7% during 2001-2005 to 32.3% during 2011-2016; for the period 2001-2016, 5-year survival was highest among Asian/Pacific Islanders (API) (42.0%), followed by Hispanics (37.2%), American Indian/Alaska Natives (AI/AN) (32.2%), Black men (31.6%), and White men (29.1%). Understanding incidence and survival differences by stage, race/ethnicity, and age can guide public health planning related to screening, treatment, and survivor care. Future research into differences by stage, race/ethnicity, and age could inform interventions aimed at improving disparities in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.